Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Journal: The Lancet. Oncology
Published: April 18, 2022
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Journal: Leukemia & lymphoma
Published: November 09, 2018
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
Journal: Leukemia
Published: October 16, 2018
Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis.
Journal: Future oncology (London, England)
Published: March 24, 2018
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 21, 2017
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Journal: The Lancet. Haematology
Published: November 21, 2016
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026